annual EBITDA:
-$426.72M-$119.09M(-38.71%)Summary
- As of today (September 18, 2025), RXRX annual EBITDA is -$426.72 million, with the most recent change of -$119.09 million (-38.71%) on December 31, 2024.
- During the last 3 years, RXRX annual EBITDA has fallen by -$251.60 million (-143.67%).
- RXRX annual EBITDA is now -626.27% below its all-time high of -$58.76 million, reached on December 31, 2019.
Performance
RXRX EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly EBITDA:
-$147.57M+$35.24M(+19.28%)Summary
- As of today (September 18, 2025), RXRX quarterly EBITDA is -$147.57 million, with the most recent change of +$35.24 million (+19.28%) on June 30, 2025.
- Over the past year, RXRX quarterly EBITDA has dropped by -$58.87 million (-66.37%).
- RXRX quarterly EBITDA is now -758.65% below its all-time high of -$17.19 million, reached on March 31, 2020.
Performance
RXRX quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM EBITDA:
-$583.64M-$58.87M(-11.22%)Summary
- As of today (September 18, 2025), RXRX TTM EBITDA is -$583.64 million, with the most recent change of -$58.87 million (-11.22%) on June 30, 2025.
- Over the past year, RXRX TTM EBITDA has dropped by -$235.29 million (-67.54%).
- RXRX TTM EBITDA is now -3296.03% below its all-time high of -$17.19 million, reached on March 31, 2020.
Performance
RXRX TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
RXRX EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -38.7% | -66.4% | -67.5% |
| 3 y3 years | -143.7% | -135.1% | -161.2% |
| 5 y5 years | -626.3% | -743.6% | -1583.0% |
RXRX EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -143.7% | at low | -171.9% | +19.3% | -161.2% | at low |
| 5 y | 5-year | -626.3% | at low | -743.6% | +19.3% | -1583.0% | at low |
| alltime | all time | -626.3% | at low | -758.6% | +19.3% | -3296.0% | at low |
RXRX EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2025 | - | -$147.57M(-19.3%) | -$583.64M(+11.2%) |
| Mar 2025 | - | -$182.81M(+10.6%) | -$524.77M(+23.0%) |
| Dec 2024 | -$426.72M(+38.7%) | -$165.34M(+88.1%) | -$426.72M(+21.6%) |
| Sep 2024 | - | -$87.92M(-0.9%) | -$350.86M(+0.7%) |
| Jun 2024 | - | -$88.70M(+4.7%) | -$348.35M(+5.3%) |
| Mar 2024 | - | -$84.75M(-5.3%) | -$330.81M(+7.5%) |
| Dec 2023 | -$307.63M(+35.1%) | -$89.48M(+4.8%) | -$307.63M(+12.9%) |
| Sep 2023 | - | -$85.41M(+20.0%) | -$272.42M(+11.4%) |
| Jun 2023 | - | -$71.16M(+15.6%) | -$244.45M(+3.6%) |
| Mar 2023 | - | -$61.58M(+13.5%) | -$236.05M(+3.7%) |
| Dec 2022 | -$227.66M | -$54.27M(-5.5%) | -$227.67M(-3.6%) |
| Sep 2022 | - | -$57.44M(-8.5%) | -$236.12M(+5.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2022 | - | -$62.76M(+18.0%) | -$223.45M(+12.1%) |
| Mar 2022 | - | -$53.20M(-15.2%) | -$199.25M(+13.8%) |
| Dec 2021 | -$175.12M(+114.3%) | -$62.72M(+40.1%) | -$175.12M(+28.0%) |
| Sep 2021 | - | -$44.77M(+16.1%) | -$136.82M(+19.3%) |
| Jun 2021 | - | -$38.57M(+32.7%) | -$114.66M(+22.5%) |
| Mar 2021 | - | -$29.07M(+19.1%) | -$93.58M(+14.5%) |
| Dec 2020 | -$81.70M(+39.1%) | - | - |
| Dec 2020 | - | -$24.41M(+7.9%) | -$81.70M(+42.6%) |
| Sep 2020 | - | -$22.61M(+29.3%) | -$57.29M(+65.2%) |
| Jun 2020 | - | -$17.49M(+1.8%) | -$34.68M(+101.8%) |
| Mar 2020 | - | -$17.19M | -$17.19M |
| Dec 2019 | -$58.76M | - | - |
FAQ
- What is Recursion Pharmaceuticals, Inc. annual EBITDA?
- What is the all time high annual EBITDA for Recursion Pharmaceuticals, Inc.?
- What is Recursion Pharmaceuticals, Inc. annual EBITDA year-on-year change?
- What is Recursion Pharmaceuticals, Inc. quarterly EBITDA?
- What is the all time high quarterly EBITDA for Recursion Pharmaceuticals, Inc.?
- What is Recursion Pharmaceuticals, Inc. quarterly EBITDA year-on-year change?
- What is Recursion Pharmaceuticals, Inc. TTM EBITDA?
- What is the all time high TTM EBITDA for Recursion Pharmaceuticals, Inc.?
- What is Recursion Pharmaceuticals, Inc. TTM EBITDA year-on-year change?
What is Recursion Pharmaceuticals, Inc. annual EBITDA?
The current annual EBITDA of RXRX is -$426.72M
What is the all time high annual EBITDA for Recursion Pharmaceuticals, Inc.?
Recursion Pharmaceuticals, Inc. all-time high annual EBITDA is -$58.76M
What is Recursion Pharmaceuticals, Inc. annual EBITDA year-on-year change?
Over the past year, RXRX annual EBITDA has changed by -$119.09M (-38.71%)
What is Recursion Pharmaceuticals, Inc. quarterly EBITDA?
The current quarterly EBITDA of RXRX is -$147.57M
What is the all time high quarterly EBITDA for Recursion Pharmaceuticals, Inc.?
Recursion Pharmaceuticals, Inc. all-time high quarterly EBITDA is -$17.19M
What is Recursion Pharmaceuticals, Inc. quarterly EBITDA year-on-year change?
Over the past year, RXRX quarterly EBITDA has changed by -$58.87M (-66.37%)
What is Recursion Pharmaceuticals, Inc. TTM EBITDA?
The current TTM EBITDA of RXRX is -$583.64M
What is the all time high TTM EBITDA for Recursion Pharmaceuticals, Inc.?
Recursion Pharmaceuticals, Inc. all-time high TTM EBITDA is -$17.19M
What is Recursion Pharmaceuticals, Inc. TTM EBITDA year-on-year change?
Over the past year, RXRX TTM EBITDA has changed by -$235.29M (-67.54%)